Brief: NW Bio issues statement on adverse market conditions and NW bio stock decline
08/01/2016 14:15
Jan 8 (Reuters) - Northwest Biotherapeutics Inc NWBO.O : * Nw bio issues statement on adverse market conditions and nw bio stock decline * Not aware of any fundamental company-related reason for substantial decline in price of the company's stock at this time * Says looking forward to being able to initiate its phase 2 clinical trials with dcvax-direct * Says "nw bio believes that its stock is being heavily impacted by these serious adverse market conditions" * Source text for Eikon ID:nPn5TyC2b * Further company coverage NWBO.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Northwest Biotherapeutics
See all newsBrief: Northwest Biotherapeutics And The UK National Health Service Blood And Transplant Announce Collaboration To Support Dcvax®-L Production
Brief: Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Brief: Northwest Biotherapeutics Provides Update On Near Term Plans For Submission Of Marketing Authorization Application
Brief: Northwest Biotherapeutics And Advent Bioservices Announce Receipt Of License For Commercial Manufacturing At Sawston, U.K. Facility
Brief: Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB